Wednesday, July 8, 2026

pharma · Glioblastoma, IDH-wildtype · SHPH

Shuttle Pharmaceuticals Holdings

Shuttle Pharmaceuticals Holdings patent portfolio — 9 USPTO pharmaceutical patents (A61K/A61P) with grant dates, status, and loss-of-exclusivity filters.

Rockville, USA HQ
2012 Founded
5 Employees
Public company Type
SHPH · NYSE Ticker
Company details
Status
Public
HQ
Rockville, USA
Founded
2012
Employees
5
Programs
1
Drugs
1
Patents
9
Intelligence · Patents

Shuttle Pharmaceuticals Holdings patents

9 pharmaceutical patents indexed for Shuttle Pharmaceuticals Holdings. 0 expire within 24 months.

Shuttle Pharmaceuticals Holdings has 9 pharmaceutical patents in our USPTO PatentsView index (A61K/A61P). 0 expire within 24 months — use filters for patent-cliff planning.

Patent portfolio

  1. US 12357650

    Methods and compositions for cancer therapies that include delivery of halogenated thymidines and thymidine phosphorlylase inhibitors in combination with radiation

    Expires Mon Jul 10 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted
  2. US 12077515

    Selective histone deacetylase inhibitors for the treatment of human disease

    Expires Mon Aug 29 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted
  3. US 11654157

    Methods and compositions for cancer therapies that include delivery of halogenated thymidines and thymidine phosphorylase inhibitors in combination with radiation

    Expires Mon May 18 2043 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted
  4. US 11584733

    Selective histone deacetylase inhibitors for the treatment of human disease

    Expires Mon Feb 16 2043 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted
  5. US 11407723

    Selective histone deacetylase inhibitors for the treatment of human disease

    Expires Mon Aug 04 2042 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted
  6. US 11034667

    Selective histone deacetylase inhibitors for the treatment of human disease

    Expires Mon Jun 10 2041 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted
  7. US 10745352

    Dual function molecules for histone deacetylase inhibition and ataxia telangiectasia mutated activation and methods of use thereof

    Expires Mon Aug 13 2040 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted
  8. US 10730834

    Dual function molecules for histone deacetylase inhibition and ataxia telangiectasia mutated activation and methods of use thereof

    Expires Mon Jul 30 2040 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted
  9. US 9809539

    Dual function molecules for histone deacetylase inhibition and ataxia telangiectasia mutated activation and methods of use thereof

    Expires Mon Nov 02 2037 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

Frequently asked questions

How many patents does Shuttle Pharmaceuticals Holdings have?

9 published patents match the current filter (all indexed). The full portfolio is indexed from USPTO PatentsView (A61K/A61P).

When do Shuttle Pharmaceuticals Holdings patents expire?

0 patents in the full portfolio expire within 24 months. Use the expiring filters above or open individual patent pages for grant and expiration dates.